Kazia Therapeutics Limited (KZIA)

Market Cap	9.20M
Revenue (ttm)	15,650
Net Income (ttm)	-10.68M
Shares Out	24.85M
EPS (ttm)	-0.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,078
Open	0.373
Previous Close	0.365
Day's Range	0.357 - 0.389
52-Week Range	0.190 - 1.410
Beta	2.11
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2024

About KZIA

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 6, 1999
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: KZIA

Financial Performance

In 2023, KZIA's revenue was 23,000, a decrease of -14.81% compared to the previous year's 27,000. Losses were -20.47 million, -18.19% less than in 2022.

Financial numbers in AUD